CAR-T Cell Therapy Market (4th Edition) by Target Indications (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis And Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19 / CD22, EGFR, NY-ESO-1 and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    October 2022

  • Pages
    640

  • View Count
    16336

Example Insights

Global-CAR-T-Cell-Therapy-Market-Context-thumb Global-CAR-T-Cell-Therapy-Market-Development-Pipeline-thumb 	Global-CAR-T-Cell-Therapy-Market-Landscape-thumb Global-CAR-T-Cell-Therapy-Market-Key-Opinion-Leaders-thumb Global-CAR-T-Cell-Therapy-Market-Construct-Analysis-thumb
Global-CAR-T-Cell-Therapy-Market-Clinical-Trial-Analysis-thumb Global-CAR-T-Cell-Therapy-Market-List-of-Cell-Therapy-thumb Global-CAR-T-Cell-Therapy-Market-Partnerships-and-Collaborations-thumb Global-CAR-T-Cell-Therapy-Market-Funding-and-Investments-thumb Global-CAR-T-Cell-Therapy-Market-Patent-Analysis-thumb
Global-CAR-T-Cell-Therapy-Market-Likely-Growth-thumb Global-CAR-T-Cell-Therapy-Market-Distribution-by-Key-Players-thumb Global-CAR-T-Cell-Therapy-Market-Promotional-Strategies-thumb    

Overview

The cancer is the one of the leading cause of deaths, globally. In fact, as per the World Health Organization (WHO), 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities as well as the national health systems. Even though a number of treatment options are available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is still difficult to achieve. Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR-T cell therapy, a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. Overall, this highly specific and promising form of CAR-T cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. 

At present, more than 5 CAR-T therapies have been approved for several hematological malignancies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences), Breyanzi® (Bristol Myers Squibb), Abecma™ (Bristol Myers Squibb) and CARVYKTI™ (Janssen Biotech / Legend Biotech). In fact, more than 170 companies are engaged in the development of over 970 early and late-stage CAR-T therapies, worldwide. Moreover, several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. Over 6,500 patents related to CAR-T cell therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, more than 260 collaborations have been inked between several industry / academic stakeholders in order to advance the development of various pipeline candidates. To fund product development initiatives, capital investments worth more than USD 24 billion have been made by various private and public sector investors, in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the CAR-T cell therapy market is likely to witness significant growth in the foreseen future.

Scope of the Report

The “CAR-T Cell Therapy Market (4th Edition) by Target Indications (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis And Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19 / CD22, EGFR, NY-ESO-1 and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of  CAR-T-cell immunotherapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).
  • An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
  • A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
  • An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies, considering them to be KOLs, who are actively involved in R&D of CAR-T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
  • Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
  • An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents. 
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell based immunotherapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapies (Kimmtrak®).
  • Elaborate profiles of the several leading players in the domain of CAR-T cell therapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T cell therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for CAR-T cell therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of CAR-T cell therapies that are already marketed or in the late stages of development. Additionally, it features market size projections for the overall CAR-T cell therapy market, wherein opportunity has been segmented across [A] target indications (non-hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma), [B] target antigens (CD19, BCMA, CD19 / CD22 and others), Key Players and [C] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the prevalent R&D trends related to CAR-T cell therapies?
  • Which different types of clinical conditions can be treated using CAR-T cell therapies?
  • Who are the leading industry and non-industry players in this market?
  • In which geographies, extensive research on CAR-T cell therapy is being conducted?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • Who are the key investors in the CAR-T cell immunotherapy domain? 
  • Who are the key opinion leaders / experts from renowned academic and research institutes which can help drive product development efforts in this domain?
  • How is the intellectual property landscape for global CAR-T cell therapies likely to evolve in the foreseen future?
  • Who are the key service providers (CMOs / CDMOs) with capabilities to develop and manufacture CAR-T cell therapies?
  • What are the key factors that are likely to influence the evolution of the CAR-T cell immunotherapies market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the key promotional strategies used by companies having marketed products?

Contents

Table Of Contents

1. PREFACE
1.1. Chapter Overview
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapy
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3.  By Approach
3.5.3.1. Activation and Suppression Immunotherapy

3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies

3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods

3.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3.7.1. Development History
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane (TM) Domain
3.7.2.3. Endodomain
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration
3.7.6. Case Study on CD19 CAR-T Cell Therapies
3.7.6.1. Other Important Biological Targets for CAR Development

3.7.7. Challenges Associated with CAR-T Cell Therapies
3.7.7.1. Competitive Risks
3.7.7.2. Clinical Risks
3.7.7.3. Regulatory Risks
3.7.7.4. Commercial Risks
3.8. Concluding Remarks

4. CAR-T CELL THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Key Target Indication
4.2.6. Analysis by Key Target Antigen
4.2.7. Analysis by Source of T-Cells
4.2.8. Analysis by Phase of Development and Source of T-Cells
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Dosing Frequency
4.2.11. Analysis by Target Patient Segment
4.2.12. Analysis by Type of Therapy
4.2.13. Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
4.2.14. Most Active Non-Industry Players: Analysis by Number of CAR-T Cell Therapies

4.3. CAR-T Cell Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. CAR-T Cell Therapies: Competitive Analysis of Popular Target Antigens
5.2.1. Popular Targets Related to Hematological Malignancies
5.2.2. Popular Targets Related to Solid Tumors 

5.3. T-Cell Immunotherapies: CAR Construct Analysis
5.3.1. Analysis by Generation of CAR
5.3.2. Analysis by Type of scFv Antibody
5.3.3. Analysis by Type of Virus Used
5.3.4. Analysis by Type of Gene Transfer Method Used
5.3.5. Analysis by Type of Co-Stimulatory Domain

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CAR-T Cell Therapies: Clinical Trial Analysis
6.3.1. Analysis of Trials by Trial Registration Year
6.3.2. Analysis of Enrolled Patient Population by Trial Registration Year 
6.3.3. Analysis by Trial Status
6.3.4. Analysis by Trial Registration Year and Trial Status
6.3.5. Analysis by Trial Phase
6.3.6. Analysis of Enrolled Patient Population by Trial Phase
6.3.7. Analysis by Target Patient Segment
6.3.8. Analysis by Type of Sponsor / Collaborator
6.3.9. Analysis by Study Design
6.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.12. Analysis by Key Focus Areas 
6.3.13. Analysis of Trials by Geography
6.3.14. Analysis of Enrolled Patient Population by Geography

7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. CAR-T Cell Therapies: Key Opinion Leaders
7.4.1. Analysis by Type of Organization
7.4.2. Analysis by Affiliated Organization
7.4.3. Analysis by Qualification
7.4.4. Analysis by Geographical Location of KOLs
7.4.5. KOL Activeness versus KOL Strength
7.4.6. Most Prominent KOLs: Analysis by RA score
7.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. Clinical Trial Information
8.2.3. Clinical Trial Endpoints
8.2.4. Clinical Trial Results
8.2.5. Estimated Sales Revenues

8.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
8.3.1. Therapy Overview
8.3.2. Clinical Trial Information
8.3.3. Clinical Trial Endpoints
8.3.4. Clinical Trial Results
8.3.5. Estimated Sales Revenues

8.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
8.4.1. Therapy Overview
8.4.2. Clinical Trial Information
8.4.3. Clinical Trial Endpoints
8.4.4. Clinical Trial Results
8.4.5. Estimated Sales Revenues

8.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers     Squibb)
8.5.1. Therapy Overview
8.5.2. Clinical Trial Information
8.5.3. Clinical Trial Endpoints
8.5.4. Clinical Trial Results
8.5.5. Estimated Sales Revenues

8.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
8.6.1. Therapy Overview
8.6.2. Clinical Trial Information
8.6.3. Clinical Trial Endpoints
8.6.4. Clinical Trial Results
8.6.5. Estimated Sales Revenues

8.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
8.7.1. Therapy Overview
8.7.2. Clinical Trial Information
8.7.3. Clinical Trial Endpoints
8.7.4. Clinical Trial Results
8.7.5. Estimated Sales Revenues

8.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
8.8.1. Therapy Overview
8.8.2. Clinical Trial Information
8.8.3. Clinical Trial Endpoints
8.8.4. Clinical Trial Results
8.8.5. Estimated Sales Revenues

8.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
8.9.1. Therapy Overview
8.9.2. Clinical Trial Information
8.9.3. Clinical Trial Endpoints

8.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
8.10.1. Therapy Overview
8.10.2. Clinical Trial Information
8.10.3. Clinical Trial Endpoints
8.10.4. Clinical Trial Results
8.10.5. Estimated Sales Revenues

8.11. AUTO3 / CD19/22 CAR-T (Autolus)
8.11.1. Therapy Overview
8.11.2. Clinical Trial Information
8.11.3. Clinical Trial Endpoints
8.11.4. Clinical Trial Results
8.11.5. Estimated Sales Revenues

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. CAR-T Cell Therapies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year of Partnership and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Most Popular Products: Analysis by Number of Partnerships
9.3.6. Most Active Industry Players: Analysis by Number of Partnerships
9.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships

9.3.8. Analysis by Geography
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. International and Local Deals

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. CAR-T Cell Therapies: Funding and Investment Analysis
10.3.1. Analysis of Instances by Year
10.3.2. Analysis of Amount Invested by Year
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Type of Investor
10.3.5. Most Active Players: Analysis by Number of Instances
10.3.6. Most Active Investors: Analysis by Amount Invested
10.3.7. Analysis of Amount Invested by Geography
10.3.8. Most Active Investors: Analysis by Number of Funding Instances

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. CAR-T Cell Therapies: Patent Analysis
11.3.1. Analysis by Patent Publication Year
11.3.2. Analysis by Patent Application Year
11.3.3. Analysis by Geography
11.3.4. Analysis by Type of Player
11.3.5. Analysis by CPC Symbols
11.3.6. Analysis by Key Focus Area
11.3.7. Leading Players: Analysis by Number of Patents
11.3.8. CAR-T Cell Therapies: Patent Benchmarking
11.3.9. Analysis By Patent Characteristics
11.3.10. CAR-T Cell Therapies: Patent Valuation

12. CASE STUDY: CELL THERAPY MANUFACTURING
12.1. Chapter Overview
12.2. Overview of Cell Therapy Manufacturing
12.3. Cell Therapy Manufacturing Models
12.3.1. Centralized Manufacturing Model
12.3.2. Decentralized Manufacturing Model
12.4. Scalability of Cell Therapy Manufacturing Processes
12.4.1. Scale-Up
12.4.2. Scale-Out
12.5. Types of Cell Therapy Manufacturers
12.6. Key Challenges Related to Manufacturing of Cell Therapies
12.7. Key Considerations for Cell Therapy Manufacturing
12.7.1. Characterization
12.7.2. Cost of Goods
12.8. Automation of Cell Therapy Manufacturing Process
12.9. Cell Therapy Manufacturing Supply Chain
12.10. Comparison of Players Having In-House Capabilities and Contract Manufacturers
12.11. Regulatory Landscape
12.12. Future Perspectives

13. COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing to the High Price of Cell / Gene Therapies
13.3. Pricing Models for T-Cell Immunotherapies
13.3.1. Based on Associated Costs
13.3.2. Based on Availability of Competing Products
13.3.3. Based on Patient Segment
13.3.4. Based on Opinions of Industry Experts
13.4. Reimbursement related Considerations for T-cell Immunotherapies
13.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Global CAR-T Cell Therapies Market, 2022-2035
14.4.1. CAR-T Cell Therapies Market: Analysis by Target Indication
14.4.2. CAR-T Cell Therapies Market: Analysis by Target Antigen
14.4.3. CAR-T Cell Therapies Market: Analysis by Key Players
14.4.4. CAR-T Cell Therapies Market: Analysis by Geography
14.4.5. Product Wise Sales Forecast
14.4.5.1. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
14.4.5.1.1. Sales Forecast (USD Million)
14.4.5.1.2. Net Present Value
14.4.5.1.3. Value Creation Analysis

14.4.5.2. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
14.4.5.2.1. Sales Forecast (USD Million)
14.4.5.2.2. Net Present Value (USD Million)
14.4.5.2.3. Value Creation Analysis

14.4.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
14.4.5.3.1. Sales Forecast (USD Million)
14.4.5.3.2. Net Present Value (USD Million)
14.4.5.3.3. Value Creation Analysis

14.4.5.4. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
14.4.5.4.1. Sales Forecast (USD Million)
14.4.5.4.2. Net Present Value (USD Million)
14.4.5.4.3. Value Creation Analysis

14.4.5.5. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
14.4.5.5.1. Sales Forecast (USD Million)
14.4.5.5.2. Net Present Value (USD Million)
14.4.5.5.3. Value Creation Analysis

14.4.5.6. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
14.4.5.6.1. Sales Forecast (USD Million)
14.4.5.6.2. Net Present Value (USD Million)
14.4.5.6.3. Value Creation Analysis

14.4.5.7. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
14.4.5.7.1. Sales Forecast (USD Million)
14.4.5.7.2. Net Present Value (USD Million)
14.4.5.7.3. Value Creation Analysis

14.4.5.8. BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.8.1. Sales Forecast (USD Million)
14.4.5.8.2. Net Present Value (USD Million)
14.4.5.8.3. Value Creation Analysis

14.4.5.9. CD19 CAR-T (Wuhan Si'an Medical Technology)
14.4.5.9.1. Sales Forecast (USD Million)
14.4.5.9.2. Net Present Value (USD Million)
14.4.5.9.3. Value Creation Analysis

14.4.5.10. Descartes-11 (Cartesian Therapeutics)
14.4.5.10.1. Sales Forecast (USD Million)
14.4.5.10.2. Net Present Value (USD Million)
14.4.5.10.3. Value Creation Analysis

14.4.5.11. Descartes-08 (Cartesian Therapeutics)
14.4.5.11.1. Sales Forecast (USD Million)
14.4.5.11.2. Net Present Value (USD Million)
14.4.5.11.3. Value Creation Analysis

14.4.5.12. Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine)
14.4.5.12.1. Sales Forecast (USD Million)
14.4.5.12.2. Net Present Value (USD Million)
14.4.5.12.3. Value Creation Analysis

14.4.5.13. CNCT19 / HY001 (Juventas Cell Therapy)
14.4.5.13.1. Sales Forecast (USD Million)
14.4.5.13.2. Net Present Value (USD Million)
14.4.5.13.3. Value Creation Analysis

14.4.5.14. CD30.CAR-T / TT11 (Tessa Therapeutics)
14.4.5.14.1. Sales Forecast (USD Million)
14.4.5.14.2. Net Present Value (USD Million)
14.4.5.14.3. Value Creation Analysis

14.4.5.15. TAK-007 (Takeda)
14.4.5.15.1. Sales Forecast (USD Million)
14.4.5.15.2. Net Present Value (USD Million)
14.4.5.15.3. Value Creation Analysis

14.4.5.16. AUTO1 (Autolus)
14.4.5.16.1. Sales Forecast (USD Million)
14.4.5.16.2. Net Present Value (USD Million)
14.4.5.16.3. Value Creation Analysis

14.4.5.17. AUTO3 (Autolus)
14.4.5.17.1. Sales Forecast (USD Million)
14.4.5.17.2. Net Present Value (USD Million)
14.4.5.17.3. Value Creation Analysis
14.4.5.18. CD19 CAR-T (Bioray Laboratories)
14.4.5.18.1. Sales Forecast (USD Million)
14.4.5.18.2. Net Present Value (USD Million)
14.4.5.18.3. Value Creation Analysis

14.4.5.19. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.19.1. Sales Forecast (USD Million)
14.4.5.19.2. Net Present Value (USD Million)
14.4.5.19.3. Value Creation Analysis

14.4.5.20. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
14.4.5.20.1. Sales Forecast (USD Million)
14.4.5.20.2. Net Present Value (USD Million)
14.4.5.20.3. Value Creation Analysis

14.4.5.21. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
14.4.5.21.1. Sales Forecast (USD Million)
14.4.5.21.2. Net Present Value (USD Million)
14.4.5.21.3. Value Creation Analysis

14.4.5.22. BinD19 (Shenzhen BinDeBio)
14.4.5.22.1. Sales Forecast (USD Million)
14.4.5.22.2. Net Present Value (USD Million)
14.4.5.22.3. Value Creation Analysis

14.4.5.23. CARCIK-CD19 (CoImmune)
14.4.5.23.1. Sales Forecast (USD Million)
14.4.5.23.2. Net Present Value (USD Million)
14.4.5.23.3. Value Creation Analysis

14.4.5.24. PBCAR269A (Precision BioSciences / Servier)
14.4.5.24.1. Sales Forecast (USD Million)
14.4.5.24.2. Net Present Value (USD Million)
14.4.5.24.3. Value Creation Analysis

14.4.5.25. CD123 CAR-T cells Therapy (Chongqing Precision Biotechnology)
14.4.5.25.1. Sales Forecast (USD Million)
14.4.5.25.2. Net Present Value (USD Million)
14.4.5.25.3. Value Creation Analysis

14.4.5.26. BCMA CAR-T (Chongqing Precision Biotech)
14.4.5.26.1. Sales Forecast (USD Million)
14.4.5.26.2. Net Present Value (USD Million)
14.4.5.26.3. Value Creation Analysis

14.4.5.27. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.27.1. Sales Forecast (USD Million)
14.4.5.27.2. Net Present Value (USD Million)
14.4.5.27.3. Value Creation Analysis

14.4.5.28. GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology)
14.4.5.28.1. Sales Forecast (USD Million)
14.4.5.28.2. Net Present Value (USD Million)
14.4.5.28.3. Value Creation Analysis

14.4.5.29. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
14.4.5.29.1. Sales Forecast (USD Million)
14.4.5.29.2. Net Present Value (USD Million)
14.4.5.29.3. Value Creation Analysis

14.4.5.30. ALLO-501A / ALLO-501 (Allogene Therapeutics)
14.4.5.30.1. Sales Forecast (USD Million)
14.4.5.30.2. Net Present Value (USD Million)
14.4.5.30.3. Value Creation Analysis

14.4.5.31. CD19/CD20-CAR-T (Yake Biotechnology)
14.4.5.31.1. Sales Forecast (USD Million)
14.4.5.31.2. Net Present Value (USD Million)
14.4.5.31.3. Value Creation Analysis

14.4.5.32. CD7 CAR-T (PersonGen BioTherapeutics)
14.4.5.32.1. Sales Forecast (USD Million)
14.4.5.32.2. Net Present Value (USD Million)
14.4.5.32.3. Value Creation Analysis

14.4.5.33. Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics)
14.4.5.33.1. Sales Forecast (USD Million)
14.4.5.33.2. Net Present Value (USD Million)
14.4.5.33.3. Value Creation Analysis

14.4.5.34. CT053 (CARsgen Therapeutics)
14.4.5.34.1. Sales Forecast (USD Million)
14.4.5.34.2. Net Present Value (USD Million)
14.4.5.34.3. Value Creation Analysis

14.4.5.35. Anti-ALPP CAR-T Cells (TCRCure Biopharma)
14.4.5.35.1. Sales Forecast (USD Million)
14.4.5.35.2. Net Present Value (USD Million)
14.4.5.35.3. Value Creation Analysis

14.4.5.36. BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology)
14.4.5.36.1. Sales Forecast (USD Million)
14.4.5.36.2. Net Present Value (USD Million)
14.4.5.36.3. Value Creation Analysis

14.4.5.37. ALLO-605 (Allogene Therapeutics)
14.4.5.37.1. Sales Forecast (USD Million)
14.4.5.37.2. Net Present Value (USD Million)
14.4.5.37.3. Value Creation Analysis

14.4.5.38. WU CART 007 (Wugen)
14.4.5.38.1. Sales Forecast (USD Million)
14.4.5.38.2. Net Present Value (USD Million)
14.4.5.38.3. Value Creation Analysis

14.4.5.39. CT103A (Nanjing IASO Biotherapeutics)
14.4.5.39.1. Sales Forecast (USD Million)
14.4.5.39.2. Net Present Value (USD Million)
14.4.5.39.3. Value Creation Analysis

15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website Analysis
15.4. Summary of Patient Support Services and Informative Downloads
15.5. Kymriah®: Promotional Analysis
15.5.1. Drug Overview
15.5.2. Product Website Analysis
15.5.2.1. Message for Healthcare Professionals
15.5.2.2. Message for Patients
15.5.2.3. Informative Downloads
15.5.3. Patient Support Services

15.6. Yescarta®: Promotional Analysis
15.6.1. Drug Overview
15.6.2. Product Website Analysis
15.6.2.1. Message for Healthcare Professionals
15.6.2.2. Message for Patients
15.6.2.3. Informative Downloads
15.6.3. Patient Support Services

15.7. Tecartus®: Promotional Analysis
15.7.1. Drug Overview
15.7.2. Product Website Analysis
15.7.2.1. Message for Healthcare Professionals
15.7.2.2. Message for Patients
15.7.2.3. Informative Downloads
15.7.3. Patient Support Services
15.8. Breyanzi®: Promotional Analysis
15.8.1. Drug Overview
15.8.2. Product Website Analysis
15.8.2.1. Message for Healthcare Professionals
15.8.2.2. Message for Patients
15.8.2.3. Informative Downloads
15.8.3. Patient Support Services

15.9. Abecma®: Promotional Analysis
15.9.1. Drug Overview
15.9.2. Product Website Analysis
15.9.2.1. Message for Healthcare Professionals
15.9.2.2. Message for Patients
15.9.2.3. Informative Downloads
15.9.3. Patient Support Services
 
15.10. Carvykti®: Promotional Analysis
15.10.1. Drug Overview
15.10.2. Product Website Analysis
15.10.2.1. Message for Healthcare Professionals
15.10.2.2. Message for Patients
15.10.2.3. Informative Downloads
15.10.3. Patient Support Services

16. COMPANY PROFILES
16.1. Chapter Overview
16.2. Alaunos Therapeutics
16.3. Autolus
16.4. Bluebird Bio
16.5. Bristol Myers Squibb
16.6. Carsgen Therapeutics
16.7. Cellectis
16.8. Cellular Biomedicine Group
16.9. Gilead Sciences
16.10. Innovative Cellular Therapeutics
16.11. Kuur Therapeutics
16.12. Noile-Immune Biotech
16.13. Novartis
16.14. Shanghai GeneChem
16.15. Sinobioway Cell Therapy
16.16. Takara Bio
16.17. Wellington Zhaotai Therapies

17. CONCLUDING REMARKS
18 EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Glycostem Therapeutics
18.2.1. Interview Transcript: Troels Jordansen, Chief Executive Officer

18.2. Gracell Biotechnologies
18.2.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer

18.3. TxCell
18.3.1. Interview Transcript: Miguel Forte, Chief Operating Officer
18.4. Kite Pharma
18.4.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs

18.5. Celyad
18.5.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys

18.6. Waisman Biomanufacturing
18.6.1. Interview Transcript: Brian Dattilo, Manager of Business Development

18.7. Theravectys
18.7.1. Interview Transcript: Aino Kalervo, Former Competitive Intelligence Manager, Strategy & Business Development

18.8. Changhai Hospital
18.8.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology

18.9. University of Colorado
18.9.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Development History of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR-T Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR-T Cell Therapies
Figure 4.1 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 4.2 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 4.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 4.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 CAR-T Cell Therapies: Distribution by Key Target Indication
Figure 4.6 CAR-T Cell Therapies: Distribution by Key Target Antigen
Figure 4.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Figure 4.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cells
Figure 4.9 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 4.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Figure 4.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Figure 4.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 4.13 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Figure 4.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.15 CAR-T Cell Therapy Developers Distribution by Year of Establishment
Figure 4.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Figure 4.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18 CAR-T Cell Therapies: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 5.2 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Figure 5.3 CAR-Construction: Distribution by Generation of CAR
Figure 5.4 CAR-Construction: Distribution by Type of scFv Antibody
Figure 5.5 CAR-Construction: Distribution by Type of Virus Used
Figure 5.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 5.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 6.1 Clinical Trial Analysis: Scope and Methodology
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution of trials by Trial Registration Year, Pre-2013-2022
Figure 6.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2022
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 6.6 Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Figure 6.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 6.8 Clinical Trial Analysis: Distribution by Target Patient
Figure 6.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.10 Clinical Trial Analysis: Distribution by Study Design
Figure 6.11 Most Active Players: Distribution by Number of Registered Trials
Figure 6.12 Most Active Players: Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Key Focus Areas
Figure 6.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 6.15 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 6.16 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 6.17 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 7.1 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 7.2 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 7.3 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Figure 7.4 CAR-T Cell Therapies: Geographical Distribution of KOLs
Figure 7.5 CAR-T Cell Therapies Scatter Plot: KOL Activenes s versus KOL Strength
Figure 7.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 7.7 Most Prominent KOLs: Distribution by RA Score
Figure 7.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 7.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 8.1 Kymriah: Estimated Sales Revenues
Figure 8.2 Yescarta: Estimated Sales Revenues
Figure 8.3 Tecartus: Estimated Sales Revenues
Figure 8.4 Breyanzi: Estimated Sales Revenues
Figure 8.5 Abecma: Estimated Sales Revenues
Figure 8.6 Carvykti: Estimated Sales Revenues
Figure 8.7 Carteyva: Estimated Sales Revenues
Figure 8.8 AUTO1: Estimated Sales Revenues
Figure 8.9 AUTO3: Estimated Sales Revenues
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Figure 9.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 9.5 Partnerships and Collaborations: Distribution by Type of partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Figure 9.7 Most Popular Products: Distribution by Number of Partnerships
Figure 9.8 Most Active Industry Players: Distribution by Number of Partnerships
Figure 9.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 9.10 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Figure 9.11 Partnerships and Collaborations: Distribution of International and Local Deals
Figure 10.1 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Figure 10.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
Figure 10.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 10.5 Funding and Investments: Distribution by Types of Investors
Figure 10.6 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 10.7 Most Active Players: Distribution by Number of Instances
Figure 10.8 Most Active Players: Distribution by Amount Invested (USD Million
Figure 10.9 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 11.3 Patent Analysis: Cumulative Distribution Patent Application Year
Figure 11.4 Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 11.5 Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 11.6 Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Figure 11.7 Patent Analysis: Distribution by Geography
Figure 11.8 Patent Analysis: Distribution by Type of Player
Figure 11.9 Patent Analysis: Distribution by CPC Symbols
Figure 11.10 Patent Analysis: Key Focus Area
Figure 11.11 Leading Industry Players: Distribution by Number of Patents
Figure 11.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.14 Patent Analysis (Top 9 CPC Symbols): Benchmarking by Leading Players
Figure 11.15 Patent Analysis: Distribution by Patent Age
Figure 11.14 CAR-T Cell Therapies: Patent Valuation Analysis
Figure 12.1 Steps for Manufacturing Cell Therapies
Figure 12.2 Centralized Manufacturing: Process Model
Figure 12.3 Decentralized Manufacturing: Process Model
Figure 12.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 12.5 Cell Therapy: Challenges and Drivers
Figure 12.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 12.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 12.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 13.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 14.1 Global CAR-T Cell Therapies Market, 2022-2035 (USD Billion)
Figure 14.2 CAR-T Cell Therapies Market: Distribution by Target Indication(s), 2025 and 2035 (USD Billion)
Figure 14.3 CAR-T Cell Therapies Market: Distribution by Target Antigen(s), 2025 and 2035 (USD Billion)
Figure 14.4 CAR-T Cell Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 14.5 CAR-T Cell Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 14.6 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Figure 14.7 Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 14.8 Tecartus (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 14.9 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 14.10 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Figure 14.11 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 14.12 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.13 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.14 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.15 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.16 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.17 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Figure 14.18 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Figure 14.19 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.20 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Figure 14.21 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 14.22 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 14.23 CD19 CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 14.24 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, till 2035 (USD Million)
Figure 14.25 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.26 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2035 (USD Million)
Figure 14.27 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Figure 14.28 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Figure 14.29 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Figure 14.30 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.31 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, till 2035 (USD Million)
Figure 14.32 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.33 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.34 IC9-CAR19 T Cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Figure 14.35 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.36 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.37 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.38 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.39 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.40 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 14.41 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.42 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.43 WU CART 007 (WUGEN) Sales Forecast, till 2035 (USD Million)
Figure 14.44 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 15.1 Channels Used for Promotional Campaigns
Figure 15.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 15.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 15.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 15.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 15.6 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 15.7 Product Website Analysis: Yescarta, Messages for Patients
Figure 15.8 Product Website Analysis: Yescarta, Kite Konnect
Figure 15.9 Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 15.10 Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 15.11 Product Website Analysis: Tecartus, Messages for Patients
Figure 15.12 Product Website Analysis: Tecartus, Kite Konnect
Figure 15.13 Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 15.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 15.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 15.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 15.17 Product Website Analysis: Abecma, Messages for Patients
Figure 15.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 15.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 15.20 Product Website Analysis: Carvykti, Messages for Patients
Figure 15.21 Product Website Analysis: Carvykti, MyCARVYKTI
Figure 17.1 Concluding Remarks: Market Landscape
Figure 17.2 Concluding Remarks: Clinical Trial Analysis
Figure 17.3 Concluding Remarks: Key Opinion Leaders
Figure 17.4 Concluding Remarks: Partnerships & Collaborations
Figure 17.5 Concluding Remarks: Funding and Investment Analysis
Figure 17.6 Concluding Remarks: Patent Analysis
Figure 17.7 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 Biosensors in Drug Discovery: List of Companies
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.5 Key Characteristics of CAR-T Cells
Table 3.6 Comparison of First and Second-Generation CAR-Ts
Table 3.7 CD19 CAR-T Cells: Preclinical Results
Table 3.8 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 4.1 CAR-T Cell Therapies: Clinical Pipeline
Table 4.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 4.3 CAR-T Cell Therapies: Preclinical Pipeline
Table 4.4 List of CAR-T cells Developers
Table 5.1 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 8.1 CAR-T Cell Therapies: List of Therapies Profiled
Table 8.2 Therapy Profile: Kymriah® (Novartis)
Table 8.3 Kymriah: Clinical Trial Information
Table 8.4 Kymriah: Clinical Trial Endpoints
Table 8.5 Kymriah: Clinical Trial Results
Table 8.6 Therapy Profile: Yescarta (Gilead Sciences)
Table 8.7 Yescarta: Clinical Trial Information
Table 8.8 Yescarta: Clinical Trial Endpoints
Table 8.9 Yescarta: Clinical Trial Results
Table 8.10 Therapy Profile: Tecartus (Gilead Sciences)
Table 8.11 Tecartus: Clinical Trial Information
Table 8.12 Tecartus: Clinical Trial Endpoints
Table 8.13 Tecartus: Clinical Trial Results
Table 8.14 Therapy Profile: Breyanzi (Bristol Myers Squibb)
Table 8.15 Breyanzi: Clinical Trial Information
Table 8.16 Breyanzi: Clinical Trial Endpoints
Table 8.17 Breyanzi: Clinical Trial Results
Table 8.18 Therapy Profile: Abecma (Bristol Myers Squibb)
Table 8.19 Abecma: Clinical Trial Information
Table 8.20 Abecma: Clinical Trial Endpoints
Table 8.21 Abecma: Clinical Trial Results
Table 8.22 Therapy Profile: Carvykti (Janssen)
Table 8.23 Carvykti: Clinical Trial Information
Table 8.24 Carvykti: Clinical Trial Endpoints
Table 8.25 Carvykti: Clinical Trial Results
Table 8.26 Therapy Profile: Carteyva (JW Therapeutics)
Table 8.27 Carteyva: Clinical Trial Information
Table 8.28 Carteyva: Clinical Trial Endpoints
Table 8.29 Carteyva: Clinical Trial Results
Table 8.30 Therapy Profile: TBI-1501 (Takara Bio)
Table 8.31 TBI-1501: Clinical Trial Information
Table 8.32 TBI-1501: Clinical Trial Endpoints
Table 8.33 Therapy Profile: AUTO1 (Autolus)
Table 8.34 AUTO1: Clinical Trial Information
Table 8.35 AUTO1: Clinical Trial Endpoints
Table 8.36 AUTO1: Clinical Trial Results
Table 8.37 Therapy Profile: AUTO3 (Autolus)
Table 8.38 AUTO3: Clinical Trial Information
Table 8.39 AUTO3: Clinical Trial Endpoints
Table 8.40 AUTO3: Clinical Trial Results
Table 9.1 CAR-T Cell Therapies: List of Partnerships and Collaborations, 2005-2022
Table 10.1 CAR-T Cell Therapies: Funding and Investments, 2000-2022
Table 10.2 CAR-T Cell Therapies: Summary of Investments
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.1 Assessment Strategies for Different Manufacturing Processes
Table 12.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 12.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 13.1 Price of Marketed Gene / Cell Therapies
Table 13.2 Price of Marketed Targeted Drugs
Table 13.3 CAR-T Cell Therapies: Expert Opinions on Pricing
Table 13.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 14.1 CAR-T Cell Therapies: List of Forecasted Molecules
Table 14.2 Kymriah (Novartis): Net Present Value (USD Million)
Table 14.3 Kymriah (Novartis): Value Creation Analysis (USD Million)
Table 14.4 Yescarta (Gilead Sciences): Net Present Value (USD Million)
Table 14.5 Yescarta (Gilead Sciences): Value Creation Analysis (USD Million)
Table 14.6 Tecartus: (Gilead Sciences): Net Present Value (USD Million)
Table 14.7 Tecartus: (Gilead Sciences): Value Creation Analysis (USD Million)
Table 14.8 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Net Present Value (USD Million)
Table 14.9 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 14.10 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Net Present Value (USD Million)
Table 14.11 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Value Creation Analysis (USD Million)
Table 14.12 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Net Present Value (USD Million)
Table 14.13 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 14.14 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Net Present Value (USD Million)
Table 14.15 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Value Creation Analysis (USD Million)
Table 14.16 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 14.17 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.18 CD19 CAR-T (Wuhan Si'an Medical Technology): Net Present Value (USD Million)
Table 14.19 CD19 CAR-T (Wuhan Si'an Medical Technology): Value Creation Analysis (USD Million)
Table 14.20 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 14.21 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 14.22 Descartes-08 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 14.23 Descartes-08 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 14.24 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Net Present Value (USD Million)
Table 14.25 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Value Creation Analysis (USD Million)
Table 14.26 CNCT19 / HY001 (Juventas Cell Therapy): Net Present Value (USD Million)
Table 14.27 CNCT19 / HY001 (Juventas Cell Therapy): Value Creation Analysis (USD Million)
Table 14.28 CD30.CAR-T / TT11 (Tessa Therapeutics): Net Present Value (USD Million)
Table 14.29 CD30.CAR-T / TT11 (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 14.30 TAK-007 (Takeda): Net Present Value (USD Million)
Table 14.32 TAK-007 (Takeda): Value Creation Analysis (USD Million)
Table 14.33 AUTO1 (Autolus): Net Present Value (USD Million)
Table 14.34 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 14.35 AUTO3 (Autolus): Net Present Value (USD Million)
Table 14.36 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 14.37 CD19 CAR-T (Bioray Laboratories): Net Present Value (USD Million)
Table 14.38 CD19 CAR-T (Bioray Laboratories): Value Creation Analysis (USD Million)
Table 18.39 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.40 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.41 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 14.42 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 14.43 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD Million)
Table 14.44 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 14.45 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 14.46 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 14.47 CARCIK-CD19 (CoImmune): Net Present Value (USD Million)
Table 14.48 CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 14.49 PBCAR269A (Precision BioSciences / Servier): Net Present Value (USD Million)
Table 14.50 PBCAR269A (Precision BioSciences and Servier): Value Creation Analysis (USD Million)
Table 14.51 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 14.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 14.53 BCMA CAR-T (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 14.54 BCMA CAR-T (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 14.55 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 14.56 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.57 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Net Present Value (USD Million)
Table 14.58 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Value Creation Analysis (USD Million)
Table 14.59 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 14.60 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 14.61 ALLO-501A / ALLO-501 (Allogene Therapeutics): Net Present Value (USD Million)
Table 14.62 ALLO-501A / ALLO-501 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 14.63 CD19/CD20-CAR-T (Yake Biotechnology): Net Present Value (USD Million)
Table 14.64 CD19/CD20-CAR-T (Yake Biotechnology): Value Creation Analysis (USD Million)
Table 14.65 CD7 CAR-T (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 14.66 CD7 CAR-T (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 14.67 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 14.68 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 14.69 CT053 (CARsgen Therapeutics): Net Present Value (USD Million)
Table 14.70 CT053 (CARsgen Therapeutics): Value Creation Analysis (USD Million)
Table 14.71 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Net Present Value (USD Million)
Table 14.72 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 14.73 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 14.74 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 14.75 ALLO-605 (Allogene Therapeutics): Net Present Value (USD Million)
Table 14.76 ALLO-605 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 14.77 WU CART 007 (WUGEN): Net Present Value (USD Million)
Table 14.78 WU CART 007 (WUGEN): Value Creation Analysis (USD Million)
Table 14.79 CT103A (Nanjing IASO Biotherapeutics): Net Present Value (USD Million)
Table 14.80 CT103A (Nanjing IASO Biotherapeutics): Value Creation Analysis (USD Million)
Table 15.1 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Table 15.2 Kymriah: Drug Overview
Table 15.3 Yescarta: Drug Overview
Table 15.4 Tecartus: Drug Overview
Table 15.5 Breyanzi: Drug Overview
Table 15.6 Abecma: Drug Overview
Table 15.7 Carvykti: Drug Overview
Table 16.1 Leading CAR-T Cell Therapy Developers
Table 16.2 Autolus: Company Profile
Table 16.3 bluebird bio: Company Profile
Table 16.4 Bristol Myers Squibb: Company Profile
Table 16.5 CARsgen Therapeutics: Company Profile
Table 16.6 Cellectis: Company Profile
Table 16.7 Cellular Biomedicine Group: Company Profile
Table 16.8 Gilead Sciences: Company Profile
Table 16.9 Innovative Cellular Therapeutics: Company Profile
Table 16.10 Kuur Therapeutics: Company Profile
Table 16.11 Noile-Immune Biotech: Company Profile
Table 16.12 Novartis: Company Profile
Table 16.13 Shanghai Genechem: Company Profile
Table 16.14 Sinobioway Cell Therapy: Company Profile
Table 16.15 Takara Bio: Company Profile
Table 16.16 Wellington Zhaotai Therapies: Company Profile
Table 19.1 CAR-T Cell Therapies: Distribution by Type of Developer
Table 19.2 CAR-T Cell Therapies: Distribution by Phase of Development
Table 19.3 CAR-T Cell Therapies: Distribution by Target Therapeutic Area
Table 19.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Table 19.5 CAR-T Cell Therapies: Distribution by Key Target Indications
Table 19.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Table 19.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cell
Table 19.9 CAR-T Cell Therapies: Distribution by Route of Administration
Table 19.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Table 19.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Table 19.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Table 19.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 19.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 19.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Table 19.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 19.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 19.18 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 19.19 CAR-T Cell Therapies Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year
Table 19.20 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 19.21 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 19.22 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 19.23 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Table 19.24 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 19.25 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 19.26 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.27 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Study Design
Table 19.28 Most Active Industry Players: Distribution by Number of Registered Trials
Table 19.29 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 19.30 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 19.31 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 19.32 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 19.33 CAR-T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 19.34 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Table 19.35 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Table 19.36 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Table 19.37 CAR-T Cell Therapies: Geographical Distribution of KOLs
Table 19.38 CAR-T Cell Therapies Most Prominent KOLs: Distribution by RA Score
Table 19.39 CAR-T Cell Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 19.40 Kymriah: Estimated Sales Revenues
Table 19.41 Yescarta: Estimated Sales Revenues
Table 19.42 Tecartus: Estimated Sales Revenues
Table 19.43 Breyanzi: Estimated Sales Revenues
Table 19.44 Abecma: Estimated Sales Revenues
Table 19.45 Carvykti: Estimated Sales Revenues
Table 19.46 Carteyva: Estimated Sales Revenues
Table 19.47 AUTO1: Estimated Sales Revenues
Table 19.48 AUTO3: Estimated Sales Revenues
Table 19.49 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 19.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.51 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Table 19.52 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 19.53 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.54 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Table 19.55 Most Popular Products: Distribution by Number of Partnerships
Table 19.56 Most Active Industry Players: Distribution by Number of Partnerships
Table 19.57 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 19.58 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 19.59 Partnerships and Collaborations: Distribution of International and Local Agreements
Table 19.60 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 – 2022
Table 19.61 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 -2022 (USD Million)
Table 19.62 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 19.63 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 19.64 Funding and Investments: Distribution by Type of Investors
Table 19.65 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Table 19.66 Most Active Players: Distribution by Number of Instances
Table 19.67 Most Active Players: Distribution by Amount Invested (USD Million)
Table 19.68 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 19.69 Most Active Investors: Distribution by Number of Funding Instances
Table 19.70 Patent Analysis: Distribution by Type of Patent
Table 19.71 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 19.72 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 19.73 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 19.74 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 19.75 CAR-T Cell Therapies Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Table 19.76 CAR-T Cell Therapies Patent Analysis: Distribution by Geography
Table 19.77 CAR-T Cell Therapies Patent Analysis: Distribution by Type of Player
Table 19.78 CAR-T Cell Therapies Patent Analysis: Distribution by CPC Symbols
Table 19.79 Leading Industry Players: Distribution by Number of Patents
Table 19.80 Leading Non-Industry Players: Distribution by Number of Patents
Table 19.81 Leading Patent Assignees: Distribution by Number of Patents
Table 19.82 Patent Analysis: Distribution by Patent Age
Table 19.83 CAR-T Therapies: Patent Valuation Analysis

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

  1. 920th Hospital of Joint Logistics Support Force 
  2. AbbVie Ventures
  3. AbCellera
  4. AbCheck
  5. AbClon
  6. Abound Bio
  7. Abzena
  8. Ac?badem Atunizade Hospital
  9. Ac?badem Labcell
  10. Acibadem University
  11. ACROBiosystems
  12. AdAlta
  13. Adaptimmune Therapeutics
  14. Adicet Bio
  15. Adimab
  16. Affiliated Hospital of Jiangnan University
  17. Affiliated Hospital of Jiangsu University
  18. Affiliated Hospital to Academy of Military Medical Sciences
  19. Affiliated Zhongshan Hospital of Dalian University
  20. AffyImmune Therapeutics
  21. AGC Biologics
  22. Agreen Biotech
  23. AK (Suzhou) Biomedical
  24. Alaunos Therapeutics
  25. Aleta Biotherapeutics
  26. Alexandria Venture Investments
  27. Allife Medical Science and Technology
  28. Allogene Therapeutics
  29. Alpha Biopharma
  30. Amgen Ventures
  31. Anhui Anke Biotechnology
  32. Anhui Provincial Hospital
  33. Antion Biosciences
  34. Appia Bio
  35. Arbele
  36. Arcellx
  37. Astellas Pharma
  38. Astrazeneca
  39. Atara Biotherapeutics
  40. August Pi and Sunyer Biomedical Research Institute
  41. Aurora Biopharma
  42. Autolus
  43. Avencell
  44. Bambino Gesù Hospital and Research Institute
  45. Bayer
  46. Baylor College of Medicine
  47. Be The Match BioTherapies
  48. Beam Therapeutics
  49. Beijing 302 Hospital
  50. Beijing Biohealthcare Biotechnology
  51. Beijing Boren Hospital
  52. Beijing Cancer Hospital
  53. Beijing Chao Yang Hospital
  54. Beijing Children's Hospital
  55. Beijing Doing Biomedical
  56. Beijing GoBroad Hospital Management
  57. Beijing HuiNengAn Biotech
  58. Beijing Immunochina Medical Science & Technology
  59. Beijing Sanbo Brain Hospital
  60. Beijing Tsinghua Chang Gung Hospital
  61. Beike Biotechnology
  62. Bellicum Pharmaceuticals
  63. Beth Israel Deaconess Medical Center (BIDMC)
  64. Bioceltech Therapeutics
  65. Bio-Gene Technology
  66. BioLife Solutions
  67. Bionomics
  68. BioNTech
  69. Bioray Laboratories
  70. Biosceptre
  71. Bluebird Bio
  72. Boya Jiyin
  73. BoYuan RunSheng Pharma (Hangzhou)
  74. Bristol-Myers Squibb
  75. Cabaletta Bio
  76. Cabaret Biotech
  77. Calibr
  78. California Institute for Regenerative Medicine (CIRM)
  79. Cancer Prevention Research Institute of Texas
  80. Cancer Research Technology
  81. Cancer Research UK
  82. Carbiogene Therapeutics
  83. Caribou Biosciences
  84. Carina Biotech
  85. Caring Cross
  86. Carisma Therapeutics
  87. CARsgen Therapeutics
  88. Cartesian Therapeutics
  89. Cartherics
  90. Case Comprehensive Cancer Center 
  91. Celgene
  92. Cell and Gene Therapy Catapult
  93. Cell Design Labs
  94. Cellectis
  95. Cellex Patient Treatment 
  96. CELLforCURE
  97. CellPoint
  98. Cellular Biomedicine Group
  99. Cellvec
  100. Celularity
  101. Celyad Oncology
  102. Center for International Blood and Marrow Transplant Research
  103. Central South University
  104. Changhai Hospital
  105. Chengdu USino Technology Biology
  106. Children’s Hospital of Philadelphia
  107. Children's Hospital and Health System Foundation
  108. Children's Hospital of Fudan University
  109. Children's Hospital of Philadelphia
  110. China Immunotech (Beijing) Biotechnology
  111. China Meitan General Hospital
  112. China Regenerative Medicine International (CRMI)
  113. Chinese Academy of Sciences
  114. Chinese PLA General Hospital
  115. Chongqing Precision Biotech
  116. Chongqing Public Health Medical Center
  117. Chongqing Sidemu Biotech
  118. Chongqing University Cancer Hospital
  119. City of Hope Medical Center
  120. CoIMMUNE
  121. Cold Spring Harbor Laboratory
  122. Columbia University
  123. CRISPR Therapeutics
  124. Cryoport
  125. CureSearch for Children's Cancer
  126. Curocell 
  127. CytoLumina Technologies
  128. CytoMed Therapeutics
  129. Cytovia Therapeutics
  130. DAIICHI SANKYO COMPANY
  131. Dana-Farber Cancer Institute
  132. Dartmouth College
  133. Delenex Therapeutics
  134. DLR German Aerospace Center
  135. Dongguan People's Hospital
  136. East Clinical Center of Oncology
  137. Eden BioCell
  138. Editas Medicine
  139. Eli Lilly
  140. Elicera Therapeutics
  141. Elpis Biopharmaceuticals
  142. Eureka Therapeutics
  143. Eutilex
  144. EXUMA Biotech
  145. Fate Therapeutics
  146. Federal Research Institute of Pediatric Hematology, Oncology and Immunology
  147. Fidelity Management & Research
  148. First Affiliated Hospital of Chengdu Medical College
  149. First Affiliated Hospital of Harbin Medical University
  150. First Affiliated Hospital of Wenzhou Medical Univeristy
  151. First Affiliated Hospital of Wenzhou Medical University
  152. First Affiliated Hospital of Zhejiang University
  153. First Affiliated Hospital Xi'an Jiaotong University
  154. First Hospital of Jilin University
  155. First People's Hospital of Foshan
  156. Five Prime Therapeutics
  157. Fondazione Matilde Tettamanti Menotti De Marchi Onlus
  158. Fondo Social La Caixa
  159. Formula Pharmaceuticals
  160. Fosun Pharmaceutical
  161. Fourth Hospital of Hebei Medical University
  162. Fraunhofer
  163. Fred Hutchinson Cancer Research
  164. Fred Hutchinson Cancer Research Center
  165. Fudan University
  166. Fujian Medical University
  167. Fundamenta Therapeutics
  168. FutureGen Biopharm
  169. G Plus Life Sciences
  170. GE Global Research
  171. GE Healthcare
  172. Genentech
  173. Genus Oncology
  174. Gilead Sciences
  175. Glycostem
  176. GlyTherix
  177. Gracell Biotechnologies
  178. Great Ormond Street Hospital for Children NHS Foundation Trust 
  179. Guangdong General Hospital
  180. Guangdong Zhaotai InVivo Biomedicine
  181. Guangzhou 8th People's Hospital
  182. Guangzhou Anjie Biomedical Technology
  183. Guangzhou First People's Hospital
  184. H. Lee Moffitt Cancer Center and Research Institute
  185. Hadassah Medical Organization
  186. Harvard University
  187. HCW Biologics
  188. Hebei Senlang Biotechnology
  189. Hebei Yanda Ludaopei Hospital
  190. Hefei Binhu Hospital
  191. Heidelberg University Hospital
  192. Henan Cancer Hospital
  193. Henan Hualong Biotechnology
  194. Henan Provincial People's Hospital
  195. Hitachi Chemical Advanced Therapeutics Solutions
  196. Horizon 2020
  197. Horizon Discovery Group
  198. Houston Methodist Hospital
  199. Hrain Biotechnology
  200. HuaDao (Shanghai) Biomedical
  201. Huai'an Second People's Hospital
  202. Huazhong University of Science and Technology
  203. Hunan Provincial People's Hospital
  204. Hunan Yongren Medical Innovation
  205. Hunan Zhaotai Yongren Biotech
  206. Hunan Zhaotai Yongren Medical Innovation
  207. IASO Biotherapeutics
  208. iCAR Bio Therapeutics
  209. iCarTAB BioMed
  210. iCell Gene Therapeutics
  211. ICON
  212. IIT MediTech (Jiangsu)
  213. ImmunoACT
  214. Imugene
  215. Inhibrx
  216. Innovative Cellular Therapeutics
  217. Innovent Biologics
  218. Institut Curie
  219. Institute of Hematology & Blood Diseases Hospital
  220. Institute of Hematology and Blood Transfusion
  221. Instituto de Salud Carlos III
  222. Intellia Therapeutics
  223. Intrexon
  224. Invectys
  225. Janssen
  226. Jiangsu Province Hospital of Traditional Chinese Medicine
  227. Jiangyin People's Hospital
  228. Jichi Medical University Hospital
  229. Jingjiang People's Hospital
  230. Jingzhou Central Hospital
  231. Jonsson Comprehensive Cancer Center
  232. Juno Therapeutics
  233. Juventas Cell Therapy
  234. JW Therapeutics
  235. KAEDI
  236. Karolinska Institute
  237. Kecellitics Biotech
  238. King's College London
  239. Kite Pharma (a Gilead Sciences Company)
  240. Kuur Therapeutics
  241. Kyverna Therapeutics
  242. Legend Biotech
  243. Leucid Bio
  244. Leukemia & Lymphoma Society
  245. Leukemia Research Foundation
  246. Life Technologies
  247. Lilly Asia Ventures
  248. Liminatus Pharma
  249. Living Pharma
  250. Lonza
  251. Loyola University Medical Center
  252. LUMICKS
  253. Lyell Immunopharma
  254. MabQuest
  255. Malaghan Institute of Medical Research
  256. Marino Biotechnology
  257. Massachusetts General Hospital
  258. MaSTherCell
  259. Max Delbrück Center for Molecular Medicine 
  260. MaxCyte
  261. Mayo Clinic
  262. MD Anderson Cancer Center
  263. Medical College of Wisconsin
  264. MedImmune
  265. Medisix Therapeutics
  266. MediTrust Health
  267. Memorial Sloan Kettering Cancer Center
  268. Merck
  269. Mie University Hospital
  270. Miltenyi Biomedicine
  271. Miltenyi Biotec
  272. Minerva Biotechnologies
  273. Mink Therapeutics
  274. Moderna
  275. MolMed (acquired by AGC Biologics)
  276. Mustang Bio
  277. Nanfang Hospital of Southern Medical University
  278. Nanjing Bioheng Biotech
  279. Nanjing Children's Hospital
  280. NantKwest
  281. Nantong University
  282. National Cancer Center Research Institute Japan
  283. National Cancer Institute
  284. National Heart, Lung and Blood Institute
  285. National Institutes of Health (NIH)
  286. National Institutes of Health Clinical Center
  287. National Taiwan University Hospital
  288. National University Hospital, Singapore
  289. Navy General Hospital
  290. NeoStem
  291. Ningbo Cancer Hospital
  292. NIPRO
  293. Nkarta
  294. Noile-Immune Biotech
  295. Notch Therapeutics
  296. Novartis
  297. Novartis Venture Fund
  298. nSAGE
  299. NSF Engineering Research Center for Cell Manufacturing Technologies
  300. Oncodesign Biotechnology
  301. Oncora Medical
  302. OncoTracker
  303. Oncternal Therapeutics
  304. Oncyte
  305. ONK Therapeutics
  306. oNKo-innate
  307. ONO Pharmaceutical
  308. Opus Bio
  309. OrbiMed Advisors
  310. Ospedale Pediatrico Bambino Gesù (OPBG)
  311. Otsuka Pharmaceutical
  312. Ottawa Hospital Research Institute
  313. Outpace Bio
  314. Overland Pharmaceuticals
  315. Oxford Biomedica
  316. Oxford Biotherapeutics
  317. Oxford MEStar
  318. panCELLa
  319. Parker Institute for Cancer Immunotherapy
  320. Pediatric Brain Tumor Consortium
  321. Peking Union Medical College Hospital
  322. Peking University People's Hospital
  323. Peking University Shenzhen Hospital
  324. Peking University Third Hospital
  325. PeproMene Bio
  326. PersonGen BioTherapeutics
  327. Peter MacCallum Cancer Centre
  328. Pfenex
  329. Pfizer
  330. PHARMALOG Institut für klinische Forschung
  331. PhoreMost
  332. Pieris Pharmaceuticals
  333. Pierre Fabre
  334. Pinze Lifetechnology
  335. PLA General Hospital
  336. Porton Biologics
  337. Poseida Therapeutics
  338. Precigen
  339. Precision BioSciences
  340. Pregenen
  341. ProMab Biotechnologies
  342. Protheragen
  343. Qilu Hospital of Shandong University
  344. RA Capital Management
  345. Redmile Group
  346. RedoxTherapeis
  347. Refuge Biotechnologies
  348. Regeneron Pharmaceutical
  349. RenJi Hospital
  350. resTORbio
  351. Rockland Immunochemicals
  352. Roger Williams Medical Center
  353. Rosewell Park Comprehensive Cancer Center
  354. Royal Adelaide Hospital Cancer Centre
  355. Ruijin Hospital
  356. Sabz Biomedicals
  357. Sana Biotechnology
  358. Sangamo Therapeutics
  359. Sanofi
  360. Scotia Biologics
  361. Seattle Children’s Research Institute
  362. Seattle Children's Hospital
  363. Seattle Children's Research Institute
  364. Second Affiliated Hospital of Guangzhou Medical University
  365. Second Affiliated Hospital of Nanchang University
  366. Second Affiliated Hospital of Suzhou University
  367. Second Affiliated Hospital of Xi'an Jiaotong University
  368. Second Military Medical University
  369. Second Xiangya Hospital of Central South University
  370. Servier
  371. Shangai Cancer Institute
  372. Shanghai Biomed-Union Biotechnology
  373. Shanghai Bioray Laboratory
  374. Shanghai Cell Therapy Group
  375. Shanghai Changzheng Hospital
  376. Shanghai Chest Hospital
  377. Shanghai Children's Medical Center
  378. Shanghai East Hospital
  379. Shanghai GeneChem
  380. Shanghai General Hospital
  381. Shanghai International Medical Center
  382. Shanghai Jiao Tong University School of Medicine
  383. Shanghai Longyao Biotechnology
  384. Shanghai Ming Ju Biotechnology
  385. Shanghai OriginCell Therapeutics
  386. Shanghai PerHum Therapeutics
  387. Shanghai Pharmaceuticals
  388. Shanghai Public Health Clinical Center
  389. Shanghai Simnova Biotechnology
  390. Shanghai Tong Ren Hospital
  391. Shanghai Tongji Hospital
  392. Shanghai Ultra-T Immune Therapeutics
  393. Shanghai Unicar-Therapy Bio-medicine Technology
  394. Shanghai Zhongshan Hospital
  395. Shanxi Province Cancer Hospital
  396. Shariati Hospital
  397. Sheba Medical Center
  398. Shenzhen Binde Biotechnology
  399. Shenzhen BinDeBio
  400. Shenzhen Children's Hospital
  401. Shenzhen Geno-Immune Medical Institute
  402. Shenzhen Hospital of Southern Medical University
  403. Shenzhen Institute for Innovation and Translational Medicine
  404. Shenzhen Second People's Hospital
  405. Shenzhen University
  406. ShiJiaZhuang Zhongxi Children Hospital
  407. Shoreline Biosciences
  408. Sichuan Kelun-Biotech Biopharmaceutical
  409. Sichuan University
  410. Simcere Pharmaceutical
  411. Sinobioway Cell Therapy
  412. Sistema and Russian Direct Investment Fund
  413. Sorrento Therapeutics
  414. Southern Medical University
  415. Southwest Hospital
  416. SpringWorks Therapeutics
  417. St. Baldrick's Foundation
  418. St. Jude Children's Research Hospital
  419. Stage Cell Therapeutics
  420. Stand Up To Cancer
  421. Stanford University
  422. Stony Brook University
  423. Sun Yat-Sen University
  424. Syncopation Life Sciences
  425. Takara Bio
  426. Takeda Pharmaceutical
  427. TC BioPharm
  428. TCRCure Biopharma
  429. T-Curx
  430. Tehran University of Medical Sciences
  431. Tel Aviv Sourasky Medical Center
  432. Temasek
  433. Teneobio
  434. Terumo BCT
  435. Tessa Therapeutics
  436. Texas Children's Hospital
  437. The Affiliated Hospital Of Guizhou Medical University
  438. The Affiliated Hospital of Xuzhou Medical University
  439. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  440. The Beijing Pregene Science and Technology
  441. The Children's Mercy Hospital
  442. The Faris Foundation
  443. The First Affiliated Hospital of Anhui Medical University
  444. The First Affiliated Hospital of Dalian Medical University
  445. The First Affiliated Hospital of Guangdong Pharmaceutical University
  446. The First Affiliated Hospital of Kunming Medical College
  447. The First Affiliated Hospital of Nanchang University
  448. The First Affiliated Hospital of Nanjing Medical University
  449. The First Affiliated Hospital of Soochow University
  450. The First Affiliated Hospital of University of Science and Technology of China
  451. The First Affiliated Hospital of Zhejiang University
  452. The First Affiliated Hospital of Zhengzhou University
  453. The First Affiliated Hospital with Nanjing Medical University
  454. The First People's Hospital of Changzhou
  455. The First People's Hospital of Hefei
  456. The First People's Hospital of Yuhang District
  457. The First People's Hospital of Yunnan
  458. The Fourth Hospital of Hebei Medical University
  459. The General Hospital of Western Theater Command
  460. The Ohio State University
  461. The Pregene (ShenZhen) Biotechnology
  462. The Second Affiliated Hospital of Chongqing Medical University
  463. The Second Affiliated Hospital of Hainan Medical University
  464. The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
  465. The Second Hospital of Anhui Medical University
  466. The Second Hospital of Hebei Medical University
  467. The Second Hospital of Nanjing Medical University
  468. The Seventh Affilliated Hospital
  469. The Sixth Affiliated Hospital of Wenzhou Medical University
  470. The Third People's Hospital of Kunshan
  471. The Wistar Institute
  472. ThermoFisher Scientific
  473. Tianjin Medical University
  474. Tianjin Medical University General Hospital
  475. Tianjin Mycure Medical Technology
  476. Ticaros
  477. Timmune Biotech
  478. Tiziana Life Sciences
  479. Tmunity Therapeutics
  480. Tongji Hospital
  481. Tongji University
  482. TrakCel
  483. Transgene
  484. Transposagen Biopharmaceuticals
  485. TriArm Therapeutics
  486. Trinity College Dublin
  487. Tri-Service General Hospital
  488. Triumph Over Kid Cancer Foundation
  489. Tsinghua University
  490. Twist Bioscience
  491. TxCell
  492. Ucello Therapeutics
  493. UCL Business
  494. UNC Lineberger Comprehensive Cancer Center
  495. Union Stem Cell & Gene Engineering
  496. United States Department of Defense
  497. University College London
  498. University Health Network
  499. University of Alberta
  500. University of Birmingham
  501. University of California
  502. University of Colorado
  503. University of Milano-Bicocca
  504. University of Minnesota
  505. University of Munich
  506. University of North Carolina
  507. University of Pennsylvania
  508. University of South Australia
  509. University of Southern California
  510. University of Texas
  511. University of Washington
  512. University of Washington and Seattle Cancer Care Alliance
  513. University of Washington Cancer Consortium
  514. University of Zurich
  515. Uppsala University
  516. USHEALTH
  517. UTC Therapeutics
  518. UWELL Biopharma
  519. V Foundation
  520. VCN Biosciences
  521. venBio
  522. Versant Ventures
  523. Vineti
  524. ViroMed
  525. Vitruvian Networks
  526. Vivo Capital
  527. Washington University
  528. Weill Cornell Medical College
  529. Weill Medical College of Cornell University
  530. Wellington Zhaotai Therapies
  531. West China Hospital
  532. West China Hospital of Sichuan University
  533. Wugen
  534. Wuhan Bio-Raid Biotechnology
  535. Wuhan Sian Medical Technology
  536. Wuhan Union Hospital
  537. WuXi AppTec
  538. X-Body
  539. Xi'An Yufan Biotechnology
  540. Xiangya Hospital of Central South University
  541. Xiangyang Central Hospital
  542. Xijing Hospital
  543. Xinhua Hospital
  544. Xinqiao Hospital
  545. Xuanwu Hospital
  546. Xuzhou Medical University
  547. Yake Biotechnology
  548. Yamaguchi University
  549. Yan'an Affiliated Hospital of Kunming Medical University
  550. Yunnan Cancer Hospital
  551. Zhejiang Provincial People's Hospital
  552. Zhejiang Qixin Biotech
  553. Zhejiang University
  554. Zhujiang Hospital

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com